A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre- S2 particles for revaccination of healthy adult nonresponders

Joseph S. Bertino, Paul Tirrell, Richard N. Greenberg, Harry L. Keyserling, Gregory A. Poland, Dieter Gump, Mary Lou Kumar, Keith Ramsey

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

The efficacy of 10-μg and 40-μg hepatitis B vaccines was compared with that of an investigational vaccine containing pre-S1, pre-S2, and S subunit particles (mixed particle vaccine) in inducing protective anti-hepatitis B surface antigen (anti-HBs) concentrations in 46 otherwise healthy persons who previously did not develop measurable levels of antibodies to at least one complete course of vaccine. A statistically significant difference was seen in the percentage of subjects who developed protective levels of anti-HBs (≤10 mIU/mL) with three 40-μg doses of S subunit vaccine versus the other groups. One hundred percent of the 40-μg dose group developed protective anti-HBs titers. No difference in adverse effects was noted.

Original languageEnglish (US)
Pages (from-to)678-681
Number of pages4
JournalJournal of Infectious Diseases
Volume175
Issue number3
DOIs
StatePublished - 1997

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S<sub>1</sub>, and pre- S<sub>2</sub> particles for revaccination of healthy adult nonresponders'. Together they form a unique fingerprint.

Cite this